Proffered Paper - GU, prostate

LINK to Proffered Paper - GU, prostate

LINK to STREAM (needs an ESMO registration)

609O - Results from a phase I study of AMG 160, a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE®) immune therapy for metastatic castration-resistant prostate cancer (mCRPC)

The abstract concludes: AMG 160 treatment was tolerable with preliminary efficacy. Further dose exploration is ongoing; results will be updated.


611O - Abiraterone acetate plus prednisolone for hormone-naïve prostate cancer (PCa): Long-term results from metastatic (M1) patients in the STAMPEDE randomised trial (NCT00268476)

The abstract concludes: A sustained and substantial improvement in overall survival of M1 prostate cancer patients was achieved with ADT + abiraterone acetate + prednisolone, irrespective of burden of disease.